A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

CoNextions TR® Tendon Repair System Receives FDA Clearance

CoNextions Inc., an innovator in tendon repair, is pleased to announce that CoNextions TR® Tendon Repair System has received FDA 510(k) Clearance. Expected to launch in May 2022, the novel system addresses traumatic tendon lacerations in the hand, wrist, and forearm.

“We are pleased with the outcome of the FDA’s review of our 510(k) submission supported by a ninety patient clinical trial and are excited about the upcoming introduction and commercial launch of the product,” said Jeffrey Barnes, President and CEO of CoNextions.

Dan Gruppo, CoNextions Executive Vice President of Sales and Marketing, explained, “Our network of independent sales distributors is well positioned to offer the CoNextions TR device to orthopaedic surgeons both in the US and abroad as a better alternative to the current standard of care.”

Studies have demonstrated the CoNextions TR enables a stronger, faster and smoother repair of tendon lacerations. A prospective randomized clinical trial also showed a lower rate of treatment failure and rupture compared to conventional suture repairs. The CoNextions TR device is another example of CoNextions’ commitment to providing innovative and advanced solutions for soft-tissue repair leading to improved patient outcomes and surgeon experience. CoNextions Medical continues to revolutionize tendon repair®.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy